

Publication

Accelerated development of malaria monoclonal antibodies

JournalItem (Reviews, Editorials, Rezensionen, Urteilsanmerkungen etc. in einer wissenschaftlichen Zeitschrift)

ID 4655882

Author(s) Nekkab, N.; Penny, M. A.

Author(s) at UniBasel [Nekkab, Narimane](#) ; [Penny, Melissa](#) ;

Year 2022

Title Accelerated development of malaria monoclonal antibodies

Journal Cell Rep Med

Volume 3

Number 10

Pages 100786

Keywords Adult; Humans; *Antimalarials/adverse effects; Antibodies, Monoclonal/adverse effects; *Malaria/drug therapy; *Antineoplastic Agents, Immunological; M.P. are funded by the Bill and Melinda Gates Foundation (INV-002562 to MAP) to; model Target Product Profiles of next-generation seasonal interventions.

Mesh terms Adult; Humans; Antibodies, Monoclonal, adverse effects; Antimalarials, adverse effects; Malaria, drug therapy; Clinical Trials, Phase I as Topic

L9LS, a potent and safe antimalarial monoclonal antibody, demonstrated 88% protective efficacy against infection in a phase 1 trial in healthy adults.(1) These promising results are the first of many to usher in a potential new era of malaria prevention.

ISSN/ISBN 2666-3791 (Electronic)2666-3791 (Linking)

URL <https://doi.org/10.1016/j.xcrm.2022.100786>

edoc-URL <https://edoc.unibas.ch/91568/>

Full Text on edoc Available;

Digital Object Identifier DOI 10.1016/j.xcrm.2022.100786

PubMed ID <http://www.ncbi.nlm.nih.gov/pubmed/36260982>

ISI-Number MEDLINE:36260982

Document type (ISI) Journal Article, Comment